Registered title, quoted from ClinicalTrials.gov
Preoperative vs Postoperative Revascularization in Coronary Heart Disease Patients Undergoing Time-Sensitive Non-Cardiac Surgery (CHRONOS-PCI)
An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Wenzhou Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07175870, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Disease stage beyond surgical indications or estimated life expectancy <1 year
Exclusion criterion 9
Karnofsky performance score <60
Exclusion criterion 7
Eastern Cooperative Oncology Group (ECOG) performance status >2
Exclusion criterion 8
Women who are pregnant, breastfeeding, or planning pregnancy during the study period
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07175870, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 years
- Diagnosis of coronary heart disease with non-emergent indication for PCI confirmed by coronary angiography:
- Non-ST-elevation acute coronary syndrome (NSTE-ACS) at low or intermediate ischemic risk
- Chronic coronary syndrome (CCS) with one of the following anatomical characteristics (see Appendix 1 for definition):
- Moderate or severe stenosis of the left main coronary artery
- Multivessel disease involving the ostium of the left anterior descending artery
- Three-vessel disease with ≥70% stenosis in each major epicardial vessel
- Indication for time-sensitive non-cardiac surgery
- Planned non-cardiac surgery under general anesthesia in the following surgical departments: thoracic surgery, gastrointestinal surgery, colorectal surgery, hepatobiliary and pancreatic surgery, or gynecology
- For patients with malignant tumors requiring time-sensitive surgery: written informed consent confirming understanding and acceptance that, if randomized to the "PCI-first" group, their tumor surgery will be delayed until 90±14 days after PCI, with acknowledgement of potential risks (e.g., tumor progression, change in resectability)
- Ability to understand the study requirements and sign written informed consent in the language provided by the research team
Exclusion Criteria:
- Age >80 years
- Severe thrombocytopenia (platelet count <50×10⁹/L)
- Cardiogenic shock, severe heart failure (NYHA class IV, Killip class IV, or LVEF ≤35%), malignant arrhythmias (including cardiac arrest, asystole, ventricular fibrillation, or sustained ventricular tachycardia), or other life-threatening conditions requiring resuscitation
- Moderate-to-severe valvular heart disease, high-grade atrioventricular block, or other severe cardiac/pulmonary dysfunction incompatible with the planned surgery
- Planned surgery with extremely high bleeding risk (e.g., intracranial surgery, spinal surgery, retinal surgery)
- Patients with malignant tumors undergoing non-palliative surgery who are in poor general condition, defined as meeting any of the following:
- Karnofsky performance score <60
- Eastern Cooperative Oncology Group (ECOG) performance status >2
- Disease stage beyond surgical indications or estimated life expectancy <1 year
- Patients requiring emergency or urgent surgery due to critical illness
- Severe renal dysfunction: serum creatinine >442 μmol/L, GFR ≤30 mL/min/1.73 m², or currently on renal replacement therapy
- Severe hepatic dysfunction: Child-Pugh class C or higher
- Severe uncontrolled systemic infection
- Advanced dementia with significant decline in quality of life requiring full-time care and support
- Systemic thromboembolic disease (e.g., pulmonary embolism) making surgery unsuitable
- Women who are pregnant, breastfeeding, or planning pregnancy during the study period
- Severe, uncontrolled comorbid conditions continuously impairing physiological or psychological function
- Participation in another clinical study within 3 months prior to enrollment
- Any condition judged by the investigator to interfere with participation or study conduct
Quoted from ClinicalTrials.gov, NCT07175870, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07175870, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.